Target Corporation vs Tango Therapeutics Inc. — how do they compare? Target Corporation trades at $157 (market cap $69.05B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Target Corporation is far larger — about 18.5× Tango Therapeutics Inc.'s market cap, and Target Corporation pays a 3.05% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Target Corporation for 137 Days and Tango Therapeutics Inc. for 0 Days on average.
| TGT | TNGX | |
|---|---|---|
Market Cap | $69.05B | $3.74B |
Volume | 3,728,482 | 3,438,781 |
Sector | Consumer Staples | Health |
52-Week High | $169.90 | $32.90 |
52-Week Low | $83.68 | $7.50 |
Typical Hold Time | 137 Days | 0 Days |
Enterprise Value | $82.33B | $2.76B |
Dividend Yield | 3.05% | — |
Signals from Pluang's Aura AI — not financial advice
Target Corporation (TGT) trades at $151.98, down 1.04% on the day, with a neutral technical outlook. The stock shows strong fundamentals with a P/E of 15.77 and consistent earnings beats in recent quarters. Recent news highlights Target's holiday price-cutting strategy to capture market share, while analyst consensus remains positive with a $166.95 price target.
Target presents a balanced investment case with solid profitability metrics (ROE 26.41%) and stable cash flow generation. Near-term catalysts include holiday sales performance and margin benefits from tariff refunds. Key risks include competitive pressures and consumer spending volatility. Wall Street maintains a bullish bias with 47% buy ratings.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →